GURU.Markets stock price, segment price, and overall market index valuation
The company's share price ALX Oncology Holdings
ALX Oncology is a biotech company developing immuno-oncology drugs. Its stock price is heavily dependent on the results of clinical trials and partnerships with major pharmaceutical companies that validate its cancer treatment approach.
Share prices of companies in the market segment - Oncology immuno-therapy
ALX Oncology is a biopharmaceutical company developing a new generation of immuno-oncology drugs that block the CD47 ("don't eat me") signal, enabling the immune system to recognize and destroy cancer cells. We've classified it in the "Oncology Immunotherapy" segment. The chart below shows the overall dynamics in this hot biotech sector.
Broad Market Index - GURU.Markets
ALX Oncology is an oncology company developing immunotherapeutic drugs that block the CD47 signal, enabling the immune system to attack cancer cells. It is a component of the GURU.Markets index. The chart below represents the market. See how this stock compares to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
ALXO - Daily change in the company's share price ALX Oncology Holdings
For ALX Oncology Holdings, an immuno-oncology company, daily price change is a measure of extreme volatility. It reflects the market's reaction to clinical trial data and is a critical parameter in risk assessment formulas.
Daily change in the price of a set of shares in a market segment - Oncology immuno-therapy
ALX Oncology Holdings Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with ALXO's performance, which depends on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
ALX Oncology is a biotech company developing cancer immunotherapy drugs. Its shares are buoyed by anticipation of clinical trial results. These sharp, event-driven movements are part of a complex mosaic of stock market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization ALX Oncology Holdings
For ALX Oncology Holdings, the year-to-date performance is a story of developing a new approach in immuno-oncology. Its 12-month market capitalization is entirely dependent on clinical trial data for its lead drug, which blocks the CD47 ("don't eat me") signal. Successful results in combination with other drugs could make it a breakthrough in cancer treatment.
Annual dynamics of market capitalization of the market segment - Oncology immuno-therapy
ALX Oncology Holdings Inc. is a late-stage biotech developing immunotherapies for cancer treatment. Its stock performance is entirely dependent on clinical trial results and partnerships. The chart reflects the enormous potential of its scientific platform and the high risks involved.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
ALX Oncology is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where data releases are the key events.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization ALX Oncology Holdings
ALX Oncology is an immuno-oncology company. Its monthly performance is driven by progress in clinical trials of its lead drug, evoralumab. Data on its efficacy in combination with other therapies, presented at conferences, is the main driver of its valuation.
Monthly dynamics of market capitalization of the market segment - Oncology immuno-therapy
Immuno-oncology, particularly CD47 inhibitors, is one of the hottest segments in biotech. The dynamics of this sector, shown in the chart, reflect investor confidence in this new class of anti-cancer drugs. At the center of this trend is a company like ALX Oncology.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
ALX Oncology, a biopharmaceutical company focused on immuno-oncology, thrives in a world of clinical data. Its shares rise and fall on trial news, defying overall market trends. The chart demonstrates this independence.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization ALX Oncology Holdings
Shares of ALX Oncology, a biopharmaceutical company developing therapies that help the immune system recognize cancer, have been highly volatile on a weekly basis. Clinical trial data, especially in combination with other drugs, are causing sharp price movements.
Weekly dynamics of market capitalization of the market segment - Oncology immuno-therapy
ALX Oncology and the entire oncology biotech sector are riding the same news and sentiment. Breakthroughs in immunotherapy or changes in FDA policy could boost the entire industry. The chart will show how the company stacks up against this high-risk segment.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
ALX Oncology and the entire oncology biotech sector are riding the same news and sentiment. Breakthroughs in immunotherapy or changes in FDA policy could boost the entire industry. The chart will show how the company stacks up against this high-risk segment.
Market capitalization of the company, segment and market as a whole
ALXO - Market capitalization of the company ALX Oncology Holdings
ALX Oncology's market capitalization is the financial valuation of a biotech company developing a new generation of immuno-oncology drugs targeting the "don't eat me" mechanism. The chart reflects investors' high hopes for its lead drug. Its dynamics tell the story of how the market is reacting to clinical trial data in one of the hottest areas of oncology.
ALXO - Share of the company's market capitalization ALX Oncology Holdings within the market segment - Oncology immuno-therapy
ALX Oncology Holdings is a clinical-stage immuno-oncology company developing therapies that help the immune system recognize and attack cancer cells by blocking the "don't eat me" signal (CD47). Its sector share reflects its leadership in this promising field. The chart below shows the weight of this "cancer hunter."
Market capitalization of the market segment - Oncology immuno-therapy
ALX Oncology is developing a new generation of immuno-oncology drugs targeting the CD47 signaling pathway. The chart below shows the total market capitalization of this entire sector. It reflects the search for ways to make "cold" tumors "hot" and visible to the immune system. ALX is at the forefront of this field.
Market capitalization of all companies included in a broad market index - GURU.Markets
Cancer immunotherapy, visible in the chart, is looking for ways to make tumors "visible" to the immune system. ALX Oncology is developing a drug that blocks the "don't eat me" signal (CD47) used by cancer cells. Its capitalization is a bet on this promising, but competitive, approach.
Book value capitalization of the company, segment and market as a whole
ALXO - Book value capitalization of the company ALX Oncology Holdings
ALX Oncology's book value is capital for "unlocking" the immune system. Currently in the R&D stage, the company is using its financial assets for clinical trials of its lead drug, which prevents cancer cells from disguising themselves as "self" and allows the immune system to attack them.
ALXO - Share of the company's book capitalization ALX Oncology Holdings within the market segment - Oncology immuno-therapy
ALX Oncology, a clinical-stage biopharmaceutical company, is developing a new generation of immuno-oncology drugs. Its share of the sector's assets consists of R&D laboratories. Its value lies in the potential of its lead drug, which helps the immune system recognize cancer cells.
Market segment balance sheet capitalization - Oncology immuno-therapy
ALX Oncology Holdings is a clinical-stage oncology company, making its model intellectually rather than capital-intensive. The company's value lies in its lead candidate and clinical trial data. Compared to the biotech sector, its "light" balance sheet is typical of R&D companies.
Book value of all companies included in the broad market index - GURU.Markets
ALX Oncology's assets are not in chemotherapy, but in the development of a new generation of immuno-oncology drugs that help the immune system better recognize and attack cancer cells. The company's balance sheet reflects the value of its lead candidate. The chart shows how much capital is invested in decloaking tumors.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - ALX Oncology Holdings
ALX Oncology is a biopharmaceutical company developing drugs that help the immune system recognize and attack cancer cells. Its market value is determined by its lead candidate and its potential in combination with other therapies. The chart reflects its belief in its scientific approach.
Market to book capitalization ratio in a market segment - Oncology immuno-therapy
ALX Oncology is an immuno-oncology company developing drugs that help the immune system fight cancer. Its value is based on the potential of its lead candidate. This chart shows how market capitalization, based on belief in a new cancer-fighting mechanism, is unrelated to tangible assets.
Market to book capitalization ratio for the market as a whole
ALX Oncology is an oncology company developing immunotherapy. Its value is determined by the potential of this innovative technology. This chart illustrates the extent to which biotech market valuations are based on future scientific breakthroughs rather than current tangible assets, which contrasts sharply with the market average.
Debts of the company, segment and market as a whole
ALXO - Company debts ALX Oncology Holdings
ALX Oncology is a biopharmaceutical company developing next-generation immuno-oncology drugs. Advancing a lead candidate through multiple clinical trials in various combinations requires significant capital. This chart shows how the company funds its extensive clinical development program.
Market segment debts - Oncology immuno-therapy
ALX Oncology Holdings is a clinical-stage oncology company developing therapies that help the immune system recognize cancer cells. This chart shows the company's financial strategy as it advances its lead candidate through expensive clinical trials, a critical stage for any biotech company.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio ALX Oncology Holdings
ALX Oncology, a biopharmaceutical company specializing in cancer immunotherapy, is in active clinical trials. This chart shows how reliant it is on debt. For a company of this profile, debt is a way to finance the hope of a breakthrough. But if the trials fail, this debt could become unsustainable.
Market segment debt to market segment book capitalization - Oncology immuno-therapy
ALX Oncology Holdings is developing a next-generation immunotherapy that helps the immune system recognize and attack cancer cells by blocking the "don't eat me" signal. This chart compares the debt raised for this breakthrough research to the overall market capitalization of the immuno-oncology sector. It illustrates the financial implications of this innovative strategy.
Debt to book value of all companies in the market
ALX Oncology is a biopharmaceutical company developing a new generation of immuno-oncology drugs. Funding large-scale clinical trials is its primary goal. The chart shows how the company manages its debt along this path. Its financial structure, compared to the biotech market, reflects the stage of development and investor confidence.
P/E of the company, segment and market as a whole
P/E - ALX Oncology Holdings
This chart for ALX Oncology, a company developing immuno-oncology drugs, represents the valuation of its core asset. The stock price relative to the potential profit from a single key drug reflects investor confidence in its blockbuster potential. The price movement is a direct response to clinical trial data across various combinations and cancer types.
P/E of the market segment - Oncology immuno-therapy
This chart reflects the average valuation for the speculative immuno-oncology sector—the benchmark for ALX Oncology. The high valuation across the industry reflects confidence in this approach to cancer treatment. Comparison with this metric helps understand whether investors consider ALX's lead drug to be one of the most promising in this race.
P/E of the market as a whole
ALX Oncology is a biopharmaceutical company developing drugs that help the immune system recognize and attack cancer cells. Its lead candidate targets the "don't eat me" signal used by tumors. This chart shows the overall interest in oncology, providing insight into how the market views the potential of this promising immunotherapy approach and its clinical prospects.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company ALX Oncology Holdings
ALX Oncology is a clinical-stage biopharmaceutical company developing therapies that help the immune system recognize and attack cancer cells. Its lead candidate blocks the "don't eat me" signal. This chart reflects analyst expectations for this promising area of immuno-oncology and the company's key clinical trials.
%20P%2FE%20ALX%20Oncology%20Holdings&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-ALX-Oncology-Holdings&v=1772650106023 "Chart of the company's future (projected) P/E ALX Oncology Holdings")
Future (projected) P/E of the market segment - Oncology immuno-therapy
ALX Oncology Holdings is an immuno-oncology company developing a therapy that blocks the "don't eat me" signal (CD47), which cancer cells use to evade the immune system. The chart shows how the company's revenue forecast compares to the sector average. This reflects how the market views its lead candidate and its potential in combination with other drugs.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-immuno-therapy&v=1772650106024 "Future (projected) P/E graph of the market segment - Oncology immuno-therapy")
Future (projected) P/E of the market as a whole
ALX Oncology is a clinical-stage biopharmaceutical company developing therapies that help the immune system recognize and destroy cancer cells. This chart shows the company's overall risk appetite. ALX's success depends on the results of clinical trials. A positive market environment helps with funding but is no substitute for scientific data.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772650106026 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit ALX Oncology Holdings
ALX Oncology is a clinical-stage immuno-oncology company focused on blocking the CD47 signaling pathway used by tumors to evade the immune system. This chart shows the financial trajectory of the development of this new class of anticancer drugs. The results reflect investment in extensive clinical trials.
Profit of companies in the market segment - Oncology immuno-therapy
ALX Oncology is an immuno-oncology company developing therapies that help the immune system recognize and destroy cancer cells by blocking the CD47 signaling pathway. This is a promising area of cancer treatment. This chart shows the total revenue in the oncology sector, reflecting the high interest in new immunotherapy mechanisms.
Overall market profit
ALX Oncology Holdings is an immuno-oncology company developing therapies that help the immune system recognize and attack cancer cells. Its success is determined by clinical data. The business is not dependent on economic cycles, but investor sentiment and capital availability, which are influenced by the overall economic picture, are important for its development.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company ALX Oncology Holdings
ALX Oncology is a biopharmaceutical company whose lead drug aims to make cancer cells "visible" to the immune system. This is a promising area of immuno-oncology. This chart reflects analysts' expectations for the clinical and commercial success of this new approach to cancer treatment.
%20profit%20of%20the%20company%20ALX%20Oncology%20Holdings&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-ALX-Oncology-Holdings&v=1772650106059 "Graph of future (projected) profit of the company ALX Oncology Holdings")
Future (predicted) profit of companies in the market segment - Oncology immuno-therapy
ALX Oncology Holdings is developing a new generation of immuno-oncology drugs that help the immune system recognize and destroy cancer cells. This chart shows forecasts for the immunotherapy sector. The company's future profitability depends on the success of its lead drug in combination with other treatments for a wide range of oncological diseases.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-immuno-therapy&v=1772650106072 "Graph of future (predicted) profits of companies in a market segment - Oncology immuno-therapy")
Future (predicted) profit of the market as a whole
ALX Oncology Holdings is a biopharmaceutical company developing immuno-oncology drugs. Its ability to fund expensive clinical trials depends on stock market sentiment. This earnings expectations chart serves as an indicator of the overall investment climate, which determines investors' willingness to invest in long-term, risky projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772650106080 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - ALX Oncology Holdings
ALX Oncology is a biopharmaceutical company developing therapies that help the immune system recognize and destroy cancer cells. This chart reflects the high expectations of investors. The company's valuation is based on the potential of its lead drug to become a key component of combination immunotherapy.
P/S market segment - Oncology immuno-therapy
ALX Oncology is an immuno-oncology company developing a therapy that helps the immune system recognize and destroy cancer cells by blocking the "don't eat me" signal (CD47). This chart shows the average biotech valuation, which helps us understand how investors value the potential of this cutting-edge cancer treatment approach compared to other immunotherapies.
P/S of the market as a whole
ALX Oncology is a biopharmaceutical company developing therapies that help the immune system recognize and destroy cancer cells. This is at the forefront of immuno-oncology. This graph of average market revenue estimates clearly demonstrates that the company's valuation is based not on current sales, but on the potential of its lead drug.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company ALX Oncology Holdings
ALX Oncology is a biopharmaceutical company developing therapies that help the immune system recognize and destroy cancer cells. This chart reflects investor expectations for the future success of its lead drug. The valuation is based on potential revenue from its use in combination with other anticancer drugs.
%20P%2FS%20ALX%20Oncology%20Holdings&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-ALX-Oncology-Holdings&v=1772650106095 "The graph of the company's future (projected) P/S ALX Oncology Holdings")
Future (projected) P/S of the market segment - Oncology immuno-therapy
ALX Oncology is a biopharmaceutical company developing immuno-oncology drugs that help the immune system recognize and attack cancer cells. This chart compares the company's future revenue expectations with its sector. It reflects investor confidence in the potential of its lead drug in combination with other therapies.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-immuno-therapy&v=1772650106107 "Future (projected) P/S market segment graph - Oncology immuno-therapy")
Future (projected) P/S of the market as a whole
ALX Oncology is a clinical-stage immuno-oncology company developing therapies that help the immune system recognize and destroy cancer cells. This chart shows overall revenue expectations, and ALX Oncology is working on one of the key mechanisms of tumor evasion. The success of its drug could significantly enhance the effectiveness of other treatments.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772650106118 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales ALX Oncology Holdings
ALX Oncology is a clinical-stage biopharmaceutical company developing immunotherapeutic drugs for the treatment of cancer. Its revenue, shown in this chart, is generated not from sales but from upfront and milestone payments from major pharmaceutical partners through strategic alliances.
Sales of companies in the market segment - Oncology immuno-therapy
ALX Oncology is a biopharmaceutical company developing a new generation of immuno-oncology drugs that help the immune system recognize and destroy cancer cells. This chart reflects the dynamics of the oncology sector, where such breakthrough approaches to "unlocking" the immune response are among the hottest trends.
Overall market sales
ALX Oncology Holdings is an immuno-oncology company developing therapies that help the immune system recognize and attack cancer cells. Its success depends on clinical data and partnerships. Gross revenue growth, reflected in this chart, creates favorable conditions for biotechnology investment, allowing ALX to fund its extensive research programs.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company ALX Oncology Holdings
ALX Oncology Holdings is a biopharmaceutical company developing a therapy that helps the immune system recognize and attack cancer cells by blocking the "don't eat me" signal (CD47). This chart reflects analysts' expectations for the success of clinical trials of this cutting-edge approach in immuno-oncology.
%20sales%20of%20the%20company%20ALX%20Oncology%20Holdings&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-ALX-Oncology-Holdings&v=1772650106133 "Schedule of future (projected) sales of the company ALX Oncology Holdings")
Future (projected) sales of companies in the market segment - Oncology immuno-therapy
ALX Oncology Holdings is developing a new generation of immuno-oncology drugs that help the immune system recognize and destroy cancer cells by blocking the CD47 signal. This chart shows forecasts for the immuno-oncology sector, allowing us to assess how breakthrough approaches like ALX's could change the standard of cancer treatment.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-immuno-therapy&v=1772650106140 "Schedule of future (projected) sales of companies in the market segment - Oncology immuno-therapy")
Future (projected) sales of the market as a whole
ALX Oncology, an immuno-oncology company, sees this chart as a marker for the health of the biotech sector. The positive economic outlook reflected here is fueling increased venture capital funding and M&A activity, creating a favorable environment for the development and commercialization of their innovative cancer treatment approaches.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772650106144 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality ALX Oncology Holdings
ALX Oncology is a clinical-stage biopharmaceutical company focused on immuno-oncology. Its goal is to make cancer tumors more vulnerable to the immune system. This chart illustrates the cost of medical innovation, showing the investment in clinical trials to test the effectiveness of this new approach to cancer treatment.
Market segment marginality - Oncology immuno-therapy
ALX Oncology Holdings is an immuno-oncology company developing therapies that help the immune system recognize and destroy cancer cells. Their success depends on the success of clinical trials and partnerships. The chart below shows how their operating model compares to other biotech companies fighting cancer.
Market marginality as a whole
ALX Oncology is a clinical-stage biopharmaceutical company developing drugs that help the immune system recognize and attack cancer cells. This graph shows average profitability, and ALX is working on a key mechanism of cancer evasion. Their success depends on combining their therapy with other oncology drugs.
Employees in the company, segment and market as a whole
Number of employees in the company ALX Oncology Holdings
ALX Oncology is a clinical-stage immuno-oncology company. Its team, shown in this chart, is working on blocking the "don't eat me" signal used by cancer cells. The staff growth correlates with the expansion of clinical trials and the complexity of its research program.
Share of the company's employees ALX Oncology Holdings within the market segment - Oncology immuno-therapy
ALX Oncology is developing a new generation of immuno-oncology drugs targeting the CD47 signaling pathway. This chart shows the percentage of leading scientists working on this promising target that ALX represents. This is a direct indicator of its scientific leadership and potential to create a breakthrough cancer treatment.
Number of employees in the market segment - Oncology immuno-therapy
ALX Oncology is a clinical-stage biopharmaceutical company developing therapies that help the immune system recognize and destroy cancer cells. Its core asset is its team of scientists and clinicians. This chart shows how the company is scaling up to conduct late-stage clinical trials, a key step toward commercialization.
Number of employees in the market as a whole
ALX Oncology Holdings develops immuno-oncology drugs that help the immune system fight cancer. For this company, employment figures are secondary. The key growth driver is successful clinical trials, which attract investment and enable the company to hire top oncologists and biologists from around the world.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company ALX Oncology Holdings (ALXO)
ALX Oncology is a clinical-stage company developing immunotherapy. Its market capitalization reflects the market's faith in its scientific approach. This chart clearly demonstrates that the company's value is driven not by its headcount, but by the potential of its discoveries to fight cancer.
%20of%20the%20company%20ALX%20Oncology%20Holdings%20(ALXO)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-ALX-Oncology-Holdings-ALXO&v=1772650106197 "Chart of market capitalization per employee (in thousands of dollars) of the company ALX Oncology Holdings (ALXO)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
ALX Oncology Holdings is an immuno-oncology company developing therapies that help the immune system fight cancer. Its valuation depends on the success of clinical trials for its lead drug. This chart shows the value investors attribute to this potential breakthrough in cancer treatment, calculated per research team member.
%20by%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-immuno-therapy&v=1772650106207 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology immuno-therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
ALX Oncology is a clinical-stage biopharmaceutical company developing therapies that help the immune system recognize and attack cancer cells. This chart demonstrates its high market valuation per employee, as its drug candidate has the potential to be used in combination with many other cancer treatments.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772650106209 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company ALX Oncology Holdings (ALXO)
ALX Oncology is a biopharmaceutical company specializing in immuno-oncology, specifically blocking the CD47 signal (the "don't eat me" signal from cancer cells). This is an R&D company. This graph, being negative, shows the investment phase. It reflects how much capital the company is investing in each of its scientists to advance this therapy.
%20Chart%20ALX%20Oncology%20Holdings%20(ALXO)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-ALX-Oncology-Holdings-ALXO&v=1772650106227 "Company Profit Per Employee (in thousands of dollars) Chart ALX Oncology Holdings (ALXO)")
Profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
ALX Oncology (ALXO) is a biopharmaceutical company specializing in immuno-oncology. Their key development is a drug that blocks the "don't eat me" signal (CD47), which cancer cells use to defend themselves from the immune system. This graph reflects R&D efficiency: how successfully the team of scientists advances their lead candidate through multiple clinical trials.
%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-immuno-therapy&v=1772650106238 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy")
Profit per employee (in thousands of dollars) for the market as a whole
ALX Oncology Holdings is a biotech company focused on immuno-oncology. It is developing therapies that help the immune system "see" and attack cancer cells. This chart shows that the company is in an active R&D phase. High research staff costs result in negative profit per employee, which is typical for the industry during the development of a new drug.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772650106240 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee ALX Oncology Holdings (ALXO)
ALX Oncology is a biopharmaceutical company developing immuno-oncology drugs. This graph reflects future potential during clinical trials. Significant revenue per employee will only emerge after drug approval or a major partnership, demonstrating the value of their scientific approach in the fight against cancer.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-ALX-Oncology-Holdings-ALXO&v=1772650106252 "Sales chart per company employee ALX Oncology Holdings (ALXO)")
Sales per employee in the market segment - Oncology immuno-therapy
ALX Oncology is a biotech company whose main development (Evorpacept) is a CD47 blocker that "hides" cancer cells from the immune system. This chart shows the average revenue per employee in the sector. It helps assess the commercial potential and productivity of this in-demand field of immuno-oncology.
Sales per employee for the market as a whole
ALX Oncology Holdings (ALXO) is a biotech company developing a therapy that helps the immune system recognize and attack cancer cells (CD47 inhibitor). It is an R&D company. This chart shows the current (minimum) partnership revenue per scientist while the drug is in key clinical trials.
Short shares by company, segment and market as a whole
Shares shorted by company ALX Oncology Holdings (ALXO)
ALX Oncology is a biopharmaceutical company whose main asset is an inhibitor of CD47, the "don't eat me signal" that cancer cells use to defend themselves from the immune system. This is a hotly contested but competitive field. The chart shows the number of investors betting that ALX's drug will lose to Gilead or Pfizer in the same niche.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-ALX-Oncology-Holdings-ALXO&v=1772650106341 "Short Shares Chart for the Company ALX Oncology Holdings (ALXO)")
Shares shorted by market segment - Oncology immuno-therapy
ALX Oncology is working on CD47, one of the hottest areas in immuno-oncology. This chart demonstrates skepticism about this entire niche. Its growth suggests that investors are betting against the entire class of CD47 inhibitors, fearing toxicity issues (anemia), which have been noted with many companies in this field.
Shares shorted by the overall market
ALX Oncology is another player in the competitive cancer immunotherapy race. Their developments require hundreds of millions of dollars for clinical trials. This chart illustrates investors' general fear of risk. At such times, capital becomes more expensive, and for companies like ALXO, which require constant funding, growing pessimism can threaten their survival.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator ALX Oncology Holdings (ALXO)
ALX Oncology Holdings develops cancer immunotherapy, attempting to make "cold" tumors "hot" for the immune system to attack. This chart tracks the excitement surrounding their clinical developments. It helps identify when investor optimism is becoming excessive (above 70) or when shares are selling off too aggressively amid general market fears (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-ALX-Oncology-Holdings-ALXO&v=1772650106408 "RSI 14 indicator chart for the company's stock ALX Oncology Holdings (ALXO)")
RSI 14 Market Segment - Oncology immuno-therapy
ALX Oncology (ALXO) is a biotech company that targets CD47, the "shield" cancer cells use to camouflage themselves from the immune system. Their signature drug is Evorpacept. The Oncology Immunotherapy (biotech) sector thrives on news. RSI\_14\_Seg shows the "temperature" of this entire segment. It helps us understand: is ALXO's growth due to their R&D, or is the entire biotech sector overheated?
RSI 14 for the overall market
ALX Oncology (ALXO) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ALXO (ALX Oncology Holdings)
ALX Oncology (ALXO) is an immuno-oncology company developing a drug that blocks the CD47 ("don't eat me") signal to help the immune system recognize cancer. This chart shows the average price target. It reflects analysts' belief in this popular mechanism and ALXO's clinical trial data.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ALXO-ALX-Oncology-Holdings&v=1772650106427 "A chart showing analyst consensus forecasts for the expected stock price. ALXO (ALX Oncology Holdings)")
The difference between the consensus estimate and the actual stock price ALXO (ALX Oncology Holdings)
ALX Oncology (ALXO) is an oncology company developing a "blockbuster" drug (Evorpacept) that "unmasks" cancer cells (the CD47 "don't eat me" signal), allowing the immune system to attack them. This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting the high potential analysts see in their therapy.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ALXO-ALX-Oncology-Holdings&v=1772650106441 "A chart showing the difference between the consensus forecast and the actual stock price. ALXO (ALX Oncology Holdings)")
Analyst consensus forecast for stock prices by market segment - Oncology immuno-therapy
ALX Oncology is a biotech company developing a next-generation "checkpoint inhibitor" (Evorpacept), which helps the immune system "see" and attack cancer cells. This chart shows analysts' overall expectations across the immunotherapy sector, reflecting whether experts believe new checkpoints will be successful.
Analysts' consensus forecast for the overall market share price
ALX Oncology is a clinical-stage biotech company specializing in next-generation cancer therapies. It's an R&D company burning cash. This chart, reflecting the market's overall risk appetite, is vital. When optimism is high, investors fund speculative science. When pessimism ("risk-off") takes over, funding for biotechs like ALXO dries up.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index ALX Oncology Holdings
ALX Oncology is a biotech company specializing in immuno-oncology. Their signature drug is a drug that blocks the don't eat me signal (CD47), which cancer cells use to hide from the immune system. This chart is a clear indicator of their faith in R&D. Its dynamics reflect their clinical data and their ability to compete with giants working on the same CD47 target.
AKIMA Market Segment Index - Oncology immuno-therapy
ALX Oncology (ALXO) is an immuno-oncology company developing therapies that block the CD47 (don't eat me) signal used by tumors to camouflage themselves from the immune system. The chart shows the segment average index, helping investors assess how this popular and competitive target (CD47) differentiates ALXO from the sector average.
The AKIM Index for the overall market
ALX Oncology is an immuno-oncology company developing CD47 blockers (evorpacept) for the treatment of various cancers. This chart, reflecting the market average, is an indicator of risk appetite. It reveals the macro backdrop, which is critical for funding this cutting-edge yet competitive scientific field.
